01 PROBLEM STATEMENT
Safety Signals are Discovered too Late in the Case Accumulation Curve
A pharma company managing post-market pharmacovigilance across multiple products found that safety signals were identified only after significant case accumulation often months after the signal was statistically detectable.
MedWatch reports and case narratives from Argus Safety or Oracle AERS arrived in PDF and unstructured text.
Pharmacovigilance physicians manually reviewed cases looking for signal patterns, but this reactive approach meant signals were flagged only after they became obvious not when they first emerged. Regulatory agencies were
increasingly requiring proactive AI-assisted PV, and the company had no systematic signal detection capability. The cost of a missed safety signal legal liability, market withdrawal, and patient harm was unacceptable. PV operational cost was rising because every case required manual triage and CIOMS report generation consumed physician time.
02 current challenges
What the Pharma Company was Struggling with
Late
Signal detection timing
Safety signals identified only
after significant case
accumulation. Months after
signal was statistically
detectable.
Reactive
PV surveillance posture
Pharmacovigilance physicians
manually searched for signal
patterns. No proactive
systematic detection before
regulatory action.
Risk
Warning letter exposure
Regulatory agencies
increasingly require AI-assisted
PV. No systematic signal
detection capability exposed
company to warning letter risk.
Manual
PV operational cost
Every case required manual
triage. CIOMS report
generation consumed
physician time. PV operational
cost rising with case volume.
03 SOLUTION OVERVIEW
STAR’s Approach – AINE Adverse Event Signal Detector
STAR Systems deployed the AINE Adverse Event Signal Detector, ingesting MedWatch reports and case narratives
from Argus Safety or Oracle AERS API. MedWatch, EudraVigilance, and VigiBase literature feeds are integrated.
MedDRA API standardizes adverse event terminology automatically. The system flags safety signals earlier than
manual review detecting patterns in case accumulation that warrant pharmacovigilance physician investigation.
Regulatory submission API integration for ICSR electronic filing. CFR 21 Part 11 compliant audit trail on IBM PowerVS for inspection readiness. Pharmacovigilance physician reviews all AI flagged signals before regulatory action no
auto-submission. STAR provides weekly signal volume report and recalibrates the model quarterly on client case data.
AI PATTERN
Signal Detection + Case Narrative Ingestion +
CIOMS Generation
04 WORKFLOW PROCESS
Step-By-Step: How Safety Signals are Detected Proactively
Step 1 – Case Ingestion: MedWatch reports and case narratives ingested from Argus Safety or Oracle AERS API. MedDRA standardization applied automatically.
Step 2 – Literature Feed: MedWatch, EudraVigilance, and VigiBase literature feeds integrated. Global adverse event data incorporated for signal context.
Step 3 – Signal Detection: AI flags safety signals earlier in case accumulation curve. Patterns detected before they become statistically obvious to manual review.
Step 4 – Physician Triage: Pharmacovigilance physician reviews AI-flagged signals. Decides whether signal warrants regulatory action or continued monitoring.
Step 5 – CIOMS Generation: Structured CIOMS report auto-generated for physician review. PV operational cost reduced – AI handles case triage and report drafting.
Step 6 – Audit Trail: CFR 21 Part 11 compliant audit logging on IBM PowerVS. Every AI-flagged signal and physician decision captured for FDA inspection
05 KEY FEATURES
What the Detector Does
Proactive Signal Detection:
AI flags safety signals earlier in case accumulation curve than manual review. Patterns detected when they first emerge – not months later after obvious
Argus Safety and Oracle AERS Integration :
MedWatch reports and case narratives ingested from Argus Safety or Oracle AERS API automatically. No manual data entry or PDF extraction.
Global Literature Feed Integration:
MedWatch, EudraVigilance, and VigiBase literature feeds incorporated. Global adverse event context used for signal detection accuracy.
MedDRA Term Standardization:
Adverse event terminology standardized via MedDRA API automatically. Enables cross-product and cross-geography signal detection consistency.
Structured CIOMS Report Generation:
CIOMS reports auto drafted for physician review. PV operational cost reduced – AI handles case triage and report drafting work.
CFR 21 Part 11 Audit Trail:
Complete audit logging on IBM PowerVS for FDA inspection readiness. Every AI-flagged signal and physician decision captured.
06 BUSINESS OUTCOMES
What Changes After Go-Live
Earlier
Safety signal detectionProactive
PV surveillance posture vs
reactiveReduced
Warning letter riskCompliant
CFR 21 Part 11 audit trailCXO / Risk
- Safety signal detection earlier in case accumulation curve patient safety improvement.
- Regulatory relationship: proactive signal reporting vs reactive.
CFO
- Cost of missed safety signal: legal liability and market withdrawal prevented.
- PV operational cost reduced: AI handles case triage and CIOMS generation.
CEO
- Brand protection: proactive safety posture vs reactive.
- Market access protected: regulatory agencies increasingly require AI-assisted PV capability.
PV Head
- Warning letter risk reduced through systematic PV surveillance.
- Physician capacity freed from repetitive case review for strategic signal evaluation.
07 REAL-WORLD SCENARIO
A Day in the Life – Before and After
| Before | After |
|---|
| Product X accumulates 18 adverse event cases over 6 months. Pharmacovigilance physician notices signal pattern only in month 7 after case volume becomes obvious. | AI flags Product X signal pattern in month 3 after 8 cases. Pharmacovigilance physician investigates proactively. Signal reported to FDA before accumulation accelerates. |
| Regulatory agency issues warning letter: ‘Company failed to detect safety signal in timely manner.’ Legal liability and brand damage follow. | Company demonstrates proactive AI-assisted PV to regulatory agency. Signal detected early in accumulation curve. Warning letter risk reduced through systematic surveillance. |
| Pharmacovigilance physician spends 3 hours per case manually triaging and drafting CIOMS reports. PV operational cost scales linearly with case volume. | AI auto-drafts CIOMS reports for physician review. Physician reviews in 20 minutes instead of 3 hours. PV operational cost growth decoupled from case volume. |
| FDA audit asks for documentation of signal detection methodology. PV team has no systematic audit trail scrambles to reconstruct signal evaluation history. | FDA audit asks for signal detection trail. CFR 21 Part 11 compliant audit log on IBM PowerVS provides complete documentation of every AI flag and physician decision. |
08 ROI AND VALUE JUSTIFICATION
Why this Numbers Work
| Value Driver | Indicative Impact | How It Is Realised |
|---|
| Safety signal detection timing | Earlier in case accumulation curve | AI flags patterns when they first emerge, not months later after obvious. Patient safety improvement through proactive detection. |
| Warning letter risk | Reduced through systematic PV | Proactive AI-assisted surveillance demonstrates regulatory compliance. Systematic signal detection capability reduces agency enforcement risk. |
| Cost of missed safety signal | Positive ROI timeline | Legal liability and market withdrawal prevented Early signal detection allows proactive regulatory reporting before case accumulation accelerates and brand damage occurs. |
| Positive ROI timeline | Within 12-18 months of go-live | Avoided warning letter cost and PV operational savings across product portfolio exceed platform costs within four to six quarters. |
09 NEXT STEPS
01
Discovery Call
30-min call to understand your product portfolio, current PV case volume, and signal detection approach.
02
Pilot Scoping
We identify 1-2 products for a 12-week retrospective pilot. AI runs on historical case data to detect past signals.
03
Pilot Delivery
AI flags signals on your historical data. Timing compared against actual signal detection dates from PV records.
04
Business Case
Signal detection lead time improvement and PV operational cost savings measured from your pilot and presented to leadership.
